Eric Michael Sherb, Chief Financial Officer of Apimeds Pharmaceuticals US, Inc., filed an initial statement of beneficial ownership on November 2, 2026, reporting no securities beneficially owned as of the event date of December 1, 2025.

Key Highlights

  • Reporting person: Eric Michael Sherb, identified as Chief Financial Officer of Apimeds Pharmaceuticals US, Inc.
  • Event date: The date of event requiring the statement is listed as December 1, 2025.
  • No securities held: Both Table I (non-derivative securities) and Table II (derivative securities) are blank; the filing states "No securities are beneficially owned."
  • Filing type: This is an initial statement, not an amendment, filed by one reporting person.
  • Issuer ticker: The filing identifies the issuer as Apimeds Pharmaceuticals US, Inc. with trading symbol APUS.

Apimeds CFO Sherb Reports No Beneficial Ownership Upon Initial Filing

According to the filing, Eric Michael Sherb submitted a Form 3 initial statement of beneficial ownership in connection with his role as Chief Financial Officer at Apimeds Pharmaceuticals US, Inc. The issuer is identified in the filing with the ticker symbol APUS. The relationship section of the form indicates Sherb is an officer, specifically the Chief Financial Officer, and the form was filed by one reporting person.

The filing discloses that Sherb holds no beneficial ownership of any securities issued by Apimeds Pharmaceuticals US, Inc. as of the event date. Table I, covering non-derivative securities, and Table II, covering derivative securities such as puts, calls, warrants, options, and convertible securities, are both empty. The filing's explanation of responses states plainly: "No securities are beneficially owned."

The date of the event requiring the statement is listed as December 1, 2025, and the form was signed by Eric Sherb and dated November 2, 2026. No exchange is specified on the form's cover in the registered-securities table beyond the ticker symbol APUS associated with Apimeds Pharmaceuticals US, Inc.

What Was Disclosed

Eric Michael Sherb, Chief Financial Officer of Apimeds Pharmaceuticals US, Inc. (APUS), filed an initial beneficial ownership statement reporting zero direct or indirect holdings of any non-derivative or derivative securities of the issuer as of December 1, 2025.